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Summary-The behavioral effects of naltrexone and quaternary naltrexone were evaluated in two groups 
of pigeons. One group responded under a fixed-ratio schedule of food reinforcement and was trained to 
discriminate between 3.2 mg/kg morphine (i.m.) and saline. Drug-appropriate responding occurred in a 
dose-related manner to morphine, given intramuscularly and intraventricularly. When administered 
intraventricularly morphine was 50 times more potent as a discriminative stimulus and 5(rlOO times more 
potent at suppressing responding. Naltrexone, given intraventricularly and intramuscularly, attenuated the 
discriminative stimulus effects of morphine. Quaternary naltrexone was more potent at suppressing 
responding when administered intraventricularly but it failed to attenuate the discriminative stimulus 
effects of morphine. A second group of pigeons, responding under a variable-interval schedule of food 
reinforcement, was treated with 100.0 mg/kg/day of morphine. Naltrexone and quaternary naltrexone 
suppressed responding by both routes of administration. Naltrexone was approximately equipotent when 
given intramuscularly or intraventricularly, and the doses that suppressed responding were %500 times 
smaller than doses required to suppress responding in untreated pigeons. Although quaternary naltrexone 
was 1800 times more potent when given intraventricularly, the doses necessary to suppress responding 
by each route were the same as doses required in untreated pigeons. These results extend the conditions 
under which a quaternary derivative of naltrexone failed to display antagonist activity in the pigeon. The 
utility of this compound for characterizing central and peripheral mechanisms of action has not been 
established in different species and testing conditions and, therefore, appears to be appropriate only under 
conditions in which it is evaluated after systemic, as well as central, administration. 
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Because of their presumed inability to penetrate the 
blood-brain barrier (BBB), quaternary derivatives of 
opioid antagonists have been used extensively for 
studies of central and peripheral mechanisms of drug 
action (e.g. Brown and Goldberg, 1985). Typically, 
both the tertiary and quaternary forms of a com- 
pound are administered systemically; if the tertiary 
form exerts a pharmacological effect that is not 
mimicked by the quaternary form, it is often con- 
cluded that this effect was produced in the central 
nervous system (CNS). Quaternary naltrexone, the 
N-methyl derivative of the opioid antagonist nal- 
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trexone, is thought to have antagonistic properties 
similar to those of its parent compound, differing 
only in its ability to cross the blood-brain barrier 
and its lower affinity for opioid binding sites (e.g. 
Valentino, Katz, Medzihradsky and Woods, 1983). 
Consequently, under conditions in which 
systemically-administered naltrexone, but not qua- 
ternary naltrexone, attenuates the actions of opioid 
agonists, it is assumed that these agonist effects are 
mediated by the CNS. 
Many studies have shown that systemically- 
administered quaternary naltrexone is not an effective 
opioid antagonist under a variety of experimental 
conditions, however, very few experiments have dem- 
onstrated conclusively that the lack of antagonistic 
action observed with quaternary naltrexone is due, 
exclusively, to its inability to penetrate the 
blood-brain barrier. In order to directly confirm the 
hypothesis that quaternary naltrexone is an effective 
antagonist in vivo, but fails to antagonize the actions 
of morphine under some experimental conditions 
because of limited distribution to the CNS, it is 
important to demonstrate antagonism when qua- 
ternary naltrexone is administered directly into the 
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CNS. Although there are reports that systemically 
administered quaternary derivatives of opioid antag- 
onists attenuate peripherally-mediated effects of mor- 
phine (e.g. Russell, Bass, Goldberg, Schuster and 
Merz, 1982) and attenuate some ~ntrally-m~iated 
effects of morphine when administered directly into 
the CNS (e.g. Gmerek, Cowan and Woods, 1986) 
there are many situations in which these antagonists 
are used routinely despite no clear demonstration of 
antagonist activity by any route of administration. 
It was previously reported (France, Adams and 
Woods, 1985) that quaternary naltrexone, adminis- 
tered systemically or centrally, failed to attenuate the 
rate-suppressing effects of morphine in pigeons, 
whereas very small doses of naltrexone, administered 
intramuscularly (im.) or intra~rebroventricularly 
(i.c.v.), antagonized the effects of morphine. Those 
results suggested that the antagonistic actions of 
quaternary naltrexone might have been limited by 
its direct rate-suppressing effects. In light of its 
reduced binding affinity compared to naltrexone (e.g. 
Valentino, Herling, Woods, Medzihradsky and Merz, 
1981), the doses of quaternary naltrexone adminis- 
tered centrally that should have antagonized the 
effects of morphine, were doses that suppressed re- 
sponding markedly when administered alone. Thus, it 
was possible that quaternary naltrexone might antag- 
onize the effects of morphine on schedule-controlled 
behavior in pigeons, but, perhaps, only under condi- 
tions in which the direct effects of the drug could be 
avoided. One possible way of avoiding direct effects 
associated with large doses of antagonists is to eval- 
uate compounds in situations where animals are more 
sensitive to antagonistic actions. 
In the present experiments, the antagonistic actions 
of naltrexone and quaternary naltrexone were com- 
pared in pigeons trained to discriminate a small dose 
of morphine from saline and under other experi- 
mental conditions in which very small doses of opioid 
antagonists have been shown to produce behavioral 
effects. Specifically, nahrexone and quaternary nal- 
trexone given intramuscularly and intraventricularly 
were compared for their ability to attenuate the 
discriminative stimulus effects of 3.2mg/kg of mor- 
phine (i.v.) and to suppress food-maintained re- 
sponding in pigeons receiving 100.0 mg/kg/day of 
morphine. Although the rate-suppressing effects of 
opioid antagonists in untreated animals are thought 
not to be related to opioid mechanisms, the ability of 
very small doses of antagonists to suppress re- 
sponding in morphine-treated subjects is believed to 
be due to opioid actions (France and Woods, 1985a; 
Valentino et al., 1981; 1983; Young and Thompson, 
1978) and is often related to withdrawai of opioids. 
EXPERtMENT 1: DRUG DISCRIMINATION 
Method 
Subjects. Experimentally naive white Carneaux 
pigeons (Palmetto, Sumter, South Carolina) were 
deprived to 80% of their free feeding weight. The 
reduced body weight was maintained by food earned 
during experimental sessions as well as supple- 
mentary feeding (mixed grain and Purina Pigeon 
Checkers) in the home cage where grit and water were 
available continuously. 
Apparatus. Experiments were conducted in venti- 
lated, sound-attenuated operant chambers measuring 
33 x 28 x 36cm high. Three translucent response 
keys (2.4cm in diameter) were located on one wall 
25 cm above the chamber floor. In Experiment I, only 
the center and left keys were used and they could be 
illuminated by 7-W lights located behind each key. 
Food was presented through a 5 x 5cm opening 
directly below the center response key. Programming, 
recording and collection of data were accomplished 
with a Texas Instruments, Inc. (Dallas, Texas) 960A 
computer and cumulative response recorders (Ralph 
Gerbrands, Arlington, Massachusetts). 
Procedure. Pigeons were trained to discriminate 
between intramuscular injections of morphine and 
saline under a fixed-ratio 20 (FR 20) schedule of 
presentation of food. Each daily session was preceded 
by an intramuscular injection (1 mI/kg saline or 
3.2mg/kg morphine), after which the subject was 
placed in the experimental chamber for a pre- 
treatment period of 15 min. During the pretreatment 
period, the chamber was dark and key pecks had no 
programmed consequences. Upon expiration of the 
pretreatment period, the center and left keys were 
illuminated red and the pigeons could earn a 4-set 
access to mixed grain by emitting 20 consecutive 
responses on the injection-appropriate key (left key 
morphine-appropriate, center key saline-appropriate, 
for all subjects). Responses on the injection- 
inapprop~ate key reset the fixed ratio requirement on 
the appropriate key. Training sessions ended after 30 
presentations of food or 20 min, whichever occurred 
first. Two criteria had to be satisfied prior to the 
beginning of testing: (1) fewer than 20 responses 
could be emitted on the injection-inappropriate key 
prior to the first presentation of food; and (2) at least 
90% of the total session responses had to be emitted 
on the injection-appropriate key. When these criteria 
had been satisfied for 5 consecutive days (i.e. drug, 
saline, drug, drug, saline) intraventricular cannulae 
were implanted and testing began. 
Surgery. The surgical procedure was identical to 
that previously described (France et al., 1985). 
Briefly, pigeons were anaesthetized with 2.5 ml/kg of 
Chloropent (chloral hydrate and pentobarbital [Fort 
Dodge Laboratories, Inc., Fort Dodge, Iowa]) and 
5.0 mg/kg of ketamine and a chronic, indwelling, 22 g 
cannula (Plastic Products, Inc., Roanoke, Virginia) 
was implanted using stereotaxic procedures and a 
Revzin adaptor (Karten and Hodos, 1967). A 28 g 
dummy cannula (Plastic Products, Inc.) was inserted 
into the guide cannula except during infusions. The 
patency of the cannula was assessed monthly by 
radiographs taken immediately after an intra- 
ventricuIar injection (IO-20 ~1) of radioopaque dye 
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(Conray [Mallinckrodt, Inc., St. Louis, Missouri]). 
Only data obtained from experiments that were both 
preceded and followed by radiographs clearly show- 
ing diffusion of the dye throughout the ventricles 
were used in the analysis. 
Testing. After the testing criteria had been satisfied 
for 5 consecutive days and positive placement of the 
cannula had been verified radiographically, tests were 
conducted whenever subjects met criteria for con- 
secutive training days with drug and saline. Test 
sessions were identical to training sessions with the 
exception that 20 consecutive responses on either key 
produced food. Initially, dose-effect curves were de- 
termined for morphine administered intramuscularly 
or intraventricularly alone. For tests of antagonism, 
a single injection of naltrexone or quaternary nal- 
trexone was administered intramuscularly or intra- 
ventricularly 10 min prior to an intramuscular injec- 
tion of morphine (3.2 mg/kg). Morphine was admin- 
istered immediately prior to the beginning of the test 
session. For comparison, selected doses of naltrexone 
and quaternary naltrexone were administered intra- 
muscularly or intravent~cularly 10 min prior to an 
intramuscular injection of saline. 
Discrimination data are expressed as the mean 
percentage of responses emitted on the morphine- 
appropriate key + 1 SEM for 6 pigeons. Data for 
response rates are expressed as the mean number of 
responses per second* 1 SEM. Fixed doses (e.g. 
100.0 pg) were administered intraventricularly, how- 
ever, for the purposes of comparison these doses were 
converted to mg/kg body weight. Due to limited life 
of the cannulae, 13 subjects were needed to complete 
all the dostiffect curves. Data from the same 6 
subjects were used to complete a dose-effect curve for 
each compound. 
Drugs. The drugs used in this experiment were 
morphine sulfate (Mallinckrodt, Inc., St. Louis, Mis- 
souri), naltrexone hydrochloride (Endo Laboratories, 
Inc., Garden City, New York), and naltrexone meth- 
obromide (MRZ 2663BR) [quaternary naltrexone]; 
Dr H. Merz, C. H. Boehringer, Sohn, Ingelheim am 
Rhein, Federal Republic of Germany). Morphine 
and naltrexone were dissolved in sterile 0.9% saline 
for systemic administration and in sterile water for 
central administration. Naltrexone methobromide 
was dissolved in sterile water only. 
Systemic injections were made to the breast muscle 
in a volume of 1 ml/kg body weight. Central injec- 
tions of 10 ~1 were performed manually over a period 
of l-2 min with a 100 ~1 Hamilton syringe, connected 
to a 28 g injection cannula (Plastic Products, Inc.) by 
PE 20 polyethylene tubing. The injection cannufa 
protruded OS mm beyond the tip of the guide can- 
nula and was held in place for 2 min after the infusion 
in order to reduce possible backflow of fluid. 
Results 
Thirteen pigeons acquired the morphine-saline dis- 
c~mination after an average of 59 training sessions 
(range 37-75). The average duration of patency of the 
cannulae in the 5 pigeons eventually judged to have 
negative placement of the cannuIa was 5.5 + 1.3 
months. One pigeon died from causes unrelated to 
cannulation and one pigeon dislodged its cannula in 
the home cage. Six cannulae were patent at the 
termination of the experiment after an average of 
10.8 + 1.9 months. 
Morphine, administered intramuscularly or intra- 
ventricularly, produced responding on the drug- 
appropriate key in a dose-related manner and at 
larger doses suppressed food-maintained responding 
(Fig. 1). The doses of morphine required for complete 
generalization (i.e. greater than 90% drug 
appropriate responding) were 32.0-100.0 pg (0.07- 
0.23 mg/kg) intravent~cularly and 3.2-10.0 mg/kg 
intramuscularly. Morphine was approximately 50 
times more potent as a discriminative stimulus when 
administered intraventricularly. Intraventricular ad- 
ministration of 32.O-lOO.Opg of morphine sup- 
pressed responding to less than one response per set, 
while a dose of 32.0mg/kg was required to suppress 
responding to less than one response per set, when 
morphine was administered intramuscularly. Al- 
though doses of morphine larger than 100.0 pg were 
not tested intraventricularly, the difference in potency 
v- 
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Fig. 1. Dose-effect curves for morphine administered intra- 
ventricularly (closed symbols) and intramuscularly (open 
symbols) in pigeons trained to discriminate between intra- 
muscular injections of 3.2 mg/kg morphine and saline. Ordi- 
nates: upper panel, mean percentage of responses emitted on 
the mo~hin~appropriate key+ 1 SEM; lower panet, aver- 
age response rate+ 1 SEM expressed as responses per see, 
Abscissae: dose in mg/kg body weight. Data points above 
C represent control sessions that were preceded by a single 
intraventricular injection of 10 ~1 sterile water (closed sym- 
bols) or an intramuscular injection of 1 ml/kg saline (closed 
symbols). Two pigeons failed to respond after intra- 
ventricular injections of morphine larger than 32.Opg 
(0.07 mg/kg). 
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for suppressing responding by the two routes of 
administration appeared to be approximately 
lOO-fold (lower panel, Fig. 1). 
Neither naltrexone nor quaternary naltrexone sub- 
stituted completely for morphine as discriminative 
stimuli (data not shown). Naltrexone produced a 
maximum of 24.0 f 12.6% morphine-appropriate re- 
sponding at a dose of lOO.Opg (0.23 mg/kg i.c.v.). 
Quaternary naltrexone produced a maximum of 
39.7 + 15.1% morphine-appropriate responding at 
a dose of 56.0 pg (0.12 mg/kg i.c.v.). Quaternary 
naltrexone produced convulsions in two pigeons 
tested with 100.0 pg (i.c.v.). 
Injection of 100.0 pg (0.23 mg/kg) naltrexone in- 
traventricularly 10 min prior to 3.2 mg/kg morphine 
resulted in an average of 20.5 + 14.9% morphine- 
appropriate responding (Fig. 2). Thus, the discrimi- 
native stimulus effects of the training dose of mor- 
phine (3.2 mg/kg) were antagonized in a dose-related 
manner by naltrexone given by either route, and the 
potency of naltrexone as an antagonist was similar 
by the two routes of administration. The dose of 
naltrexone given intramuscularly required for a simi- 
lar degree of antagonism was 0.1 mg/kg (compare 
open and closed diamonds, Fig. 2). When adminis- 
I !i v---f 
tered in combination with 3.2 mg/kg morphine, 
effective antagonistic doses of tertiary naltrexone did 
not suppress food-maintained responding (lower 
panel, Fig. 2). 
Up to doses that suppressed responding, quatern- 
ary naltrexone failed to attenuate the discriminative 
stimulus effects of 3.2 mg/kg morphine (open and 
closed triangles, Fig. 2). A dose of 3.2mg/kg 
morphine in combination with quaternary nal- 
trexone, up to doses of lOO.Omg/kg (i.m.) and 
100.0 pg (0.23 mg/kg) (i.c.v.), produced at least 68% 
morphine-appropriate responding. Although there 
was a suggestion that 56.0 /~g quaternary naltrexone 
given intraventricularly partially attenuated the dis- 
criminative stimulus effects of 3.2 mg/kg morphine, 
three of the four pigeons not suppressed with that 
combination of doses responded 90.0 + 1.8% on the 
morphine key. Furthermore, the one pigeon that 
responded at the next largest dose of quaternary 
naltrexone (100.0 pug) in combination with morphine, 
responded 98.4% on the morphine key. When admin- 
istered 10 min prior to 3.2 mg/kg morphine, quatern- 
ary naltrexone was 3OGlOOO times more potent at 
suppressing responding by the intraventricular route. 
EXPERIMENT II: MORPHINE-TREATED PIGEONS 
Method 
Subjects. Three White Carneaux pigeons. that had 
been used in a previous experiment(France et al., 
1985), were maintained at 80% of their free-feeding 
weight and housed individually with water and grit 
available continuously. The reduced body weight was 
maintained by food earned during experimental ses- 
sions and supplementary feeding in the home cage 
(Purine Pigeons Checkers and mixed grain). These 
pigeons had been implanted with chronic, indwelling, 
intraventricular cannulae and had received intra- 
muscular and intraventricular injections of morphine, 
naltrexone, and quaternary naltrexone. 
Fig. 2. Dose-effect curves for naltrexone (diamonds) and 
quaternary naltrexone (triangles) administered 10 minutes 
prior to an injection of 3.2 mg/kg morphine (i.m.). Nal- 
trexone and quaternary naltrexone were administered intra- 
ventricularly (open symbols) or intramuscularly (closed 
symbols). Data points above M represent sessions in which 
only 3.2mg/kg morphine was administered. Two pigeons 
did not respond after intraventricular injections of qua- 
ternary naltrexone larger than 32.0 pg (0.07 mg/kg), and 
only one pigeon responded at a dose of lOO.Opg 
(0.22 mg/kg) quaternary naltrexone (i.c.v.). One pigeon did 
not respond after an injection of 32.0mg/kg quatemary 
naltrexone (i.m.), and three pigeons did not respond at a 
dose of lOO.Omg/kg quaternary naltrexone (i.m.). Other 
information as in Fig. 1. 
Apparatus. Experimental chambers, as well as ma- 
terials for controlling and recording experimental 
events, were identical to those described in Experi- 
ment I. For Experiment II, only the center response 
key was used and was illuminated green during 
periods of availability of food. 
Procedure. Responding was maintained under a 
variable-interval 30 set (VI 30”) schedule of 
presentation of food. Under this schedule, the first 
response after an average interval length of 30 set 
produced a 4-set access to mixed grain. Responses 
prior to the end of the interval were recorded but had 
no programmed consequence. 
Daily sessions consisted of five, discrete 15-min 
trials. Each trial began with a 10min pretreatment 
period, during which the chamber was dark and key 
pecks had no programmed consequences and a 5-min 
response period, during which food could be earned 
under the variable interval 30” schedule. Experi- 
mental sessions were conducted 5 days per week at 
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1500 hr, 6 hr after administration of the maintenance 
dose of morphine (0900 hr). 
Initially, pigeons were treated with 10.0 mg/kg/day 
of morphine for 28 days and sensitivity to the rate- 
suppressing effects of cumulative doses of naltrexone 
given intramuscularly was assessed weekly. Beginning 
on day 29, the maintenance dose of morphine was 
increased to 100.0 mg/kg/day. These conditions re- 
mained constant for the duration of the experiment 
(additional 150 days). 
Testing. Tests were conducted on Tuesday and 
Friday of each week and both single- and cumulative- 
dose procedures were used. For the first 6 weeks of 
the experiment, cumulative dose-effect curves for 
naltrexone were determined weekly to monitor any 
changes in sensitivity to the antagonist during treat- 
ment with morphine. The cumulative-dose procedure 
involved the administration of increasing doses of 
drug prior to each trial, such that the cumulative dose 
increased by f log unit per trial. For single dose 
experiments, a single injection of naltrexone or qua- 
ternary naltrexone, given intramuscularly or intra- 
ventricularly, was administered immediately prior to 
the first trial. Prior to some non-test sessions, pigeons 
received an intramuscular injection of saline 
(1 .O mg/kg) or an intraventricular injection of sterile 
water (10 ~1). The order in which doses and drugs 
were tested varied non-systematically between sub- 
jects and body weight was recorded for each subject 
immediately before and after each test session. 
Response rates are summarized as the mean rate 
f 1 SEM over a 5-trial test session for 3 pigeons and 
are expressed as a percentage of the non-injection 
control rates during treatment with 100.0 mg/kg/day 
of morphine. Control rates for each animal were 
averaged over all 5 trials of 18 non-injection sessions 
and these values were used to calculate percentage 
response rates and SEM. Doses required to suppress 
responding to 50% of the control rate were deter- 
mined for each subject by drawing a line between the 
data points immediately above and below the 50% 
suppression level and interpolating the dose required 
for that level of suppression. 
Drugs. The drugs, vehicle solutions and methods of 
administration were as described in Experiment I. 
Results 
Response rates were not affected by daily adminis- 
tration of 10.0 mg/kg of morphine. All three pigeons 
responded at or near 100% of the control rate 
throughout the treatment period with 10.0 mg/kg/day 
of morphine. Daily injections of lO.Omg/kg mor- 
phine did, however, produce an increase in sensitivity 
to the rate-suppressing effects of naltrexone. During 
the first week of treatment with 10.0 mg/kg/day mor- 
phine, the mean dose of naltrexone required to 
suppress responding to 50% of the control rate was 
0.64 mg/kg (Lm.). By the fourth week of treatment at 
this dose, a comparable degree of suppression was 
produced by 0.33 mg/kg. 
N P 26,6--c 
Response rates were suppressed to an average of 
16% of the control rate on the first day of 
100.0 mg/kg/day of morphine. By the second day of 
treatment, however, responding had recovered to 
44% of control. Thereafter, response rates increased 
more slowly, but failed to recover completely over the 
duration of treatment with 100.0 mg/kg/day of mor- 
phine. The average rate for the three pigeons during 
treatment with lOO.Omg/kg/day of morphine was 
61% (1.29 + 0.26 responses per set) of the control 
rate (2.11 * 0.12 responses per set). Consequently, 
the effects of naltrexone and quaternary naltrexone 
during treatment with 100.0 mg/kg/day of morphine 
were expressed as a percentage of the non-injection 
control rate during treatment with morphine. 
In the first week of 100.0 mg/kg/day of morphine, 
a dose of 0.13 mg/kg naltrexone suppressed re- 
sponding to 50% of the control rate. During the 
second week of lOO.Omg/kg/day of morphine, a 
comparable suppression was produced by a dose of 
0.06 mg/kg naltrexone. Because this sensitivity to 
naltrexone was similar to the sensitivity of pigeons 
maintained for long periods of time on 
lOO.Omg/kg/day of morphine (e.g. France and 
Woods, 1985a), experiments with single intra- 
muscular and intraventricular injections of nal- 
trexone and quaternary naltrexone began the follow- 
ing week. 
In pigeons, maintained on lOO.Omg/kg/day of 
morphine, naltrexone and quaternary naltrexone 
suppressed responding in a dose-related manner by 
both routes of administration (Fig. 3). The doses of 
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Fig. 3. Dose-effect curves for naltrexone (diamonds) and 
quaternary naltrexone (triangles) administered intra- 
ventricular (closed symbols) and intramuscular (open sym- 
bols) in three morphine-treated (100.0 mg/kg/day) pigeons 
responding under a variable interval 30” schedule of food 
presentation. Ordinate: mean response rate +I SEM ex- 
pressed as a percentage of the non-injection control rate 
during treatment with 100.0 mg/kg/day of morphine 
(1.29 + 0.26 responses per set). Abscissa: dose in mg/kg 
body weight, Intramuscular data are the means of two 
observations in each pigeon with each dose; intraventricular 
data represent single observations in each pigeon. Data 
points above C represent sessions that were preceded by a 
single intramuscular injection of 10 ~1 sterile water (closed 
symbols) or an intraventricular injection of 1 .O ml/kg saline 
(closed symbols). 
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Table I, Potencies of naltrexone and quaternary naltrexone given intraventricularly (i.c.v.) 
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Naltrexone 
> I .22d 26.01 0.03 0.05 140.7 520.2 
0.03 26.20 0.02 24.55 1.5 1.1 
‘From France t-l al., 1985. bn =4 (no morphine treatment). % = 3 (lOO.Omg/kg/day 
morphine). “Each entry represents the average dose (mg/kg) required to suppress 
responding to 50% of the non-injection control rate. 
naltrexone required to suppress responding were 
similar for both routes of administration. Naltrexone 
suppressed responding to 16.6 + 7.8% of the control 
rate at a dose of 0.1 mg/kg (i.m.), and a dose of 
32.0 pg (0.06 mg/kg) naltrexone, given intra- 
ventricularly, suppressed responding to 17.8 + 12.4% 
of the control rate. In contrast, the doses of qua- 
ternary naltrexone required to suppress responding 
were different by the two routes of administration. A 
dose of lOO.Opg quaternary naltrexone given intra- 
ventricularly suppressed response rates to less than 
10% of the control rate, whereas a greater than 
500-fold increase in dose was necessary to produce a 
comparable suppression when quaternary naltrexone 
was administered intramuscularly. 
Table 1 compares the potencies of naltrexone and 
quaternary naltrexone for suppressing food- 
maintained responding in untreated (France et al., 
1985) and morphine-treated pigeons under the same 
temporal and schedule conditions. Compared to un- 
treated pigeons, morphine-treated pigeons were 520 
times more sensitive to the rate-suppressing effects of 
naltrexone given intramuscularly and at least 40 
times more sensitive to the effects of naltrexone given 
intraventricularly. In contrast, the potencies of qua- 
ternary naltrexone for either route of administration 
were very similar between untreated and morphine- 
treated pigeons. 
In pigeons, treated daily with 100.0 mg/kg of mor- 
phine, changes in body weight during control sessions 
preceded by 10 ~1 of water (icv.) or 1 ml/kg saline 
(i.m.) were -2.3 f 0.8 g (-0.48%) and -0.2 k 0.7 g 
(-0.04%), respectively. However, rate-suppression 
produced by naltrexone and quaternary naltrexone 
was accompanied by a greater loss in body weight 
over the lf hr test session. The maximum body weight 
changes were: -5.7f2.6g (1.2%), 32.Opg qua- 
ternary naltrexone (i.c.v.); -8.7 + 2.7 g (l.S%), 
100.0 mg/kg quaternary naltrexone (i.m.); 
-6.7 f 1.7 g (1.4%), 32.0 pg naltrexone (i.c.v.); and 
- 7.0 + 0.6 g (1 S%), 1 .O mg/kg naltrexone (i.m.). 
The day after termination of treatment with mor- 
phine (i.e. 30 hr morphine abstinence), responding in 
two of the pigeons was markedly suppressed (46.4% 
and 76.9% of control), however, responding in the 
third pigeon accelerated to 200% of the non-injection 
control rate. By the second day (54 hr) after mor- 
phine, only one of the three subjects responded at less 
than 80% of its control rate. Sensitivity to the 
rate-suppressing effects of a single intraventricular 
injection of naltrexone also returned to normal 
several days after the termination of treatment with 
morphine (data not shown). During treatment with 
100.0 mg/kg/day of morphine, an injection of 32.0 pg 
naltrexone intraventricularly suppressed responding 
to 17.8% of the control response rate. Four days (i.e. 
102 hr) after the termination of treatment with mor- 
phine that dose of naltrexone failed to affect re- 
sponding (92.5% of control): 
DISCUSSION 
Pigeons trained to discriminate 3.2 mg/kg of mor- 
phine, given intramuscularly, from saline generalized 
to morphine given intraventricularly, in a dose- 
related manner. Furthermore, only l/SO of the 
effective systemic dose of morphine was required to 
produce morphine-appropriate responding by the 
intraventricular route. This finding is consistent with 
previous reports (e.g. Locke and Holtzman, 1985) on 
differences in the potency of opioid agonists as 
discriminative stimuli when administered centrally 
and peripherally and supports previous suggestions 
(e.g. Shannon and Holtzman, 1977) that this action 
of morphine might be mediated in the CNS. Further- 
more, the similar potency of naltrexone, as an antag- 
onist, by different routes of administration in pigeons 
was consistent with its known lipophilicity and rapid 
distribution throughout the periphery and CNS 
(Gmerek et al., 1986; Shannon and Holtzman, 1977). 
A second line of evidence, used to argue that many 
behavioral effects of opioids are mediated in the 
CNS, is differential effectiveness of systemically- 
administered tertiary and quaternary derivatives of 
narcotic antagonists. For example, in rats (Brown, 
Robertson and Goldberg, 1983; Koob, Petit, 
Ettenberg and Bloom, 1984; Russell et al., 1982), 
pigeons (France et al., 1985; Valentino et al., 1981) 
and monkeys (Hein, Young, Herling and Woods, 
1981; Valentino et al., 1981), systemically- 
administered quaternary naltrexone fails to antago- 
nize the actions of morphine that are antagonized by 
systemically-administered naltrexone. Because nal- 
trexone attenuates the effects of morphine in situ- 
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ations in which quaternary naltrexone is ineffective, 
it is thought that these effects of morphine are 
mediated centrally. The critical assumptions upon 
which these conclusions are founded, regarding the 
sites of action of opioids, are that quaternary na- 
ltrexone is an effective antagonist but does not pene- 
trate the blood-brain barrier. As discussed elsewhere 
(Brown and Goldberg, 1985), the assumptions are 
not well supported under a variety of testing condi- 
tions in viuo, despite demonstrations of antagonistic 
actions by quaternary derivatives in vitro (e.g. Va- 
lentino et al., 1981). While there are examples of 
opioid antagonistic actions after central adminis- 
tration of quaternary antagonists (Brown ef al., 1983; 
Gmerek et al., 1986; Locke and Holtzman, 1985) 
many experiments that have used quaternary deriva- 
tives have not administered these compounds cen- 
trally. Thus, although there is considerable evidence 
indicating that the discriminative stimulus effects of 
morphine (Locke and Holtzman, 1985; Shannon and 
Holtzman, 1977) and naltrexone (Holtzman, 1985; 
Valentino et al., 1981) are mediated in the CNS, the 
results of the present study fail to support the gener- 
ality of these results. Although morphine was 50 
times more potent as a discriminative stimulus when 
administered intraventricularly, data obtained with 
quaternary naltrexone given intraventricularly, failed 
to provide additional supportive evidence of the 
central site of action of morphine as a discriminative 
stimulus. In doses up to those that suppressed re- 
sponding, quaternary naltrexone, given intra- 
ventricularly, failed to attenuate the discriminative 
stimulus effects of morphine. 
The conditions necessary for the development of 
supersensitivity to the behavioral actions of opioid 
antagonists vary between species and experimental 
procedures. There are, however, two pharma- 
cological interventions by which supersensitivity has 
been shown to develop: repeated injections of large 
doses of antagonists and treatment with moderate to 
large doses of morphine, either acutely or chronically. 
Under both of these conditions, the doses of na- 
loxone or naltrexone that disrupt schedule-controlled 
behavior are l/l&l/lOOO of the doses required in 
untreated animals. However, neither in squirrel mon- 
keys made supersensitive by repeated injections of 
large doses of naltrexone (Warren and Morse, 1985) 
nor in pigeons made supersensitive by chronic treat- 
ment with 100.0 mg/kg/day of morphine (Valentino 
et al., 1981; 1983), was there an increase in the 
potency of systemically-administered quaternary 
naltrexone. Furthermore, systemically-administered 
quaternary antagonists do not precipitate withdrawal 
in morphine-dependent monkeys (Valentino et al., 
1983) or dogs (Russell et al., 1982). Because there is 
consistently no increase in sensitivity to quaternary 
naltrexone in situations where there is an increase in 
sensitivity to naltrexone, it has been assumed that 
these effects of naltrexone are central in origin. 
Quaternary naltrexone does not mimic the actions of 
naltrexone, presumably, because it does not penetrate 
the blood-brain barrier. 
It appears as though supersensitivity to naltrexone, 
after repeated exposure to large dose of naltrexone, 
does not develop in pigeons (Goldberg, Morse and 
Goldberg, 1981); however, pigeons treated acutely 
(France and Woods, 1985b) or chronically (France 
and Woods 1985a; Young and Thompson, 1978) with 
morphine are extremely sensitive to the behavioral 
effects of naltrexone. In agreement with previous 
reports (Valentino et al., 1981; 1983), systemically- 
administered naltrexone was more potent than qua- 
ternary naltrexone in suppressing food-maintained 
responding in morphine-treated pigeons. Further- 
more, centrally administered naltrexone and qua- 
ternary naltrexone were approximately equipotent at 
suppressing responding in morphine-treated pigeons. 
Those data alone might indicate that these two 
compounds suppressed responding by the same or 
similar mechanisms when administered intra- 
ventricularly in morphine-treated pigeons and that 
this suppression was related to withdrawal of opioids. 
However, dose-effect curves, determined prior to 
treatment with morphine (France et al., 1985), indi- 
cated that the potency of quaternary naltrexone given 
intraventricularly was not markedly affected by daily 
injections of morphine. It is unlikely, therefore, that 
suppression of responding by quaternary naltrexone 
was related to the precipitation of withdrawal be- 
cause the same potency and behavioral effects were 
observed in untreated pigeons. These results clearly 
indicate a lack of antagonistic activity to opioids by 
quaternary naltrexone, particularly because increased 
sensitivity to the actions of antagonists in morphine- 
treated animals has been shown to be an extremely 
sensitive indicator of antagonistic action (France 
and Woods, 1985a; Gellert and Holtzman, 1979; 
Valentino et al., 1983). 
Many quaternary opioids have lower affinity than 
their tertiary forms for opioid binding sites (e.g. 
Kosterlitz and Waterfield, 1975); quaternary nal- 
trexone, for example, has approximately a 50-fold 
lower affinity than naltrexone (Valentino et al., 1981; 
1983). Quaternary antagonists also are not highly 
specific and have been shown to bind to a variety of 
receptor types (e.g. Argentieri and McArdle, 1983). It 
is possible, therefore, that some non-opioid action of 
quaternary naltrexone accounts for its rate- 
suppressing effects, both in untreated and in 
morphine-treated pigeons, and that this effect pre- 
cludes an antagonist activity for quaternary nal- 
trexone using schedule-controlled behavior in 
pigeons. Quaternary naltrexone might, however, 
share other effects with naltrexone that are related to 
opioid withdrawal, as indicated by the similar weight 
loss observed after administration of naltrexone or 
quaternary naltrexone in morphine-treated pigeons. 
Finally, because quaternary derivatives, in general, 
do not pass readily through biological membranes, 
quaternary naltrexone may not distribute widely 
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within the CNS when administered intraventricularly 
in pigeons. Thus, the antagonistic actions of qua- 
ternary naltrexone given intraventricularly might 
be restricted to pe~vent~cular sites. ~,~-Diallyi 
nalorphine, a hydrophilic derivative of nalorphine, 
attenuates the effects of heroin in rats, as measured 
by an increase in the rate of self-administration of 
heroin, but only when injected to specific regions of 
the brain (Britt and Wise, 1983). Injections of qua- 
ternary naltrexone to discrete areas of the brain 
might also result in antagonistic actions to opioids in 
pigeons. 
The results of these experiments suggest that the 
use of quaternary derivatives for determining central 
and peripheral mechanisms of action requires these 
compounds be administered over a wide range of 
doses, centrally as well as ~ripherally. Undoubtedly, 
the appropriate use of quaternary naltrexone in other 
species (e.g. Locke and Holtzman, 1985) has provided 
valuable information on the sites of action of opioids 
and, furthermore, the results reported here may be 
restricted to a single species or, perhaps, to some 
measures of the action of drugs that utilize scheduie- 
controlled behavior. Nevertheless, the assumption 
that antagonist activity cannot be observed with 
systemically-administered quaternary derivatives 
only because these compounds do not cross the 
blood-brain barrier is not widely supported. Failure 
to characterize the spectrum of action of quaternary 
derivatives under particular testing conditions could 
lead to erroneous conclusions regarding central and 
peripheral mechanisms of action of opioids. 
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